Harmony Biosciences (HRMY) Tops Q1 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- US stock futures rise as oil pullback amplifies Fed rate-hike boost
- Oil falls 3% to one-week low as supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Harmony Biosciences Reports First Quarter 2022 Financial Results and Business Updates
May 3, 2022 7:30 AM EDTWAKIX® (pitolisant) Net Revenue of $85.3 Million for First Quarter 2022 Increase of 43% vs. the Same Period in 2021
WAKIX Surpasses $500 Million in Cumulative Net Revenue Since Launch
Initiated Phase 3 Clinical Trial in Patients with Idiopathic Hypersomnia
Conference Call and Webcast to be Held Today at 8:30 a.m. ETÂ
PLYMOUTH MEETING, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Harmony or the Company) (Nasdaq: HRMY), a pharmaceutical company focused on delivering innovative therapies that improve the health of people living with... More
